Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.

Abstract excerpt

OBJECTIVES: To evaluate, in a large real-world cohort of people living with HIV (PLWH) treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or dolutegravir/lamivudine, rates of virological failure (VF) and resistance emergence. METHODS: All PLWH receiving BIC/FTC/TAF or dolutegravir/lamivudine without prior NRTI or integrase strand transfer inhibitor (InSTI) resistance-associated mutations...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Amides
• Share to Emtricitabine